Chronic cerebrovascular diseases: pathogenetic heterogeneity and therapeutic strategies
https://doi.org/10.21518/2079-701X-2018-18-50-55
Abstract
The article presents a modern view of the pathogenic mechanisms of cerebrovascular diseases was Observed that currently available data indicate the existence of different variants of ischemic lesions of the brain and their clinical manifestations. Based on the available data and the results of our own studies, it is concluded that therapeutic strategies in patients with CVD should take into account the variety of clinical manifestations, the existence of various options for ischemic lesions of the brain substance, especially the course of the disease, heterogeneity of pathogenetic mechanisms and risk factors, as well as multi-morbidity of patients. Discusses the use of the drug Vazobral in CVD.
About the Authors
E. V. Kostenko
Pirogow City Clinical Hospital
Russian Federation
Russian Federation
Moscow
M. A. Eneeva
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine of Moscow Healthcare Department
Russian Federation
Russian Federation
References
1. Vorobieva OV, Repina VV. Open comparative observational study of the effectiveness and safety of adaptol in the treatment of anxiety-asthenic disorders in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii Im. S.S. Korsakova, 2016, 116 (3): 20-24.
2. Vorobeva OV, Rusaya VV. Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii Im. S.S. Korsakova, 2016, 116 (13): 49-54
3. Komaba Y. et al. Impaired Neurovascular Coupling by Transhemispheric Diaschisis in Rat Cerebral Cortex. Journal of Cerebral Blood Flow & Metabolism. 2004, 24: 713-719.
4. Chukanova EI. Chronic cerebral ischemia: the possibility of using Vasobral. Pharmateca, 2009, 7: 54-58.
5. Путилина М.В. Хроническая ишемия головного мозга. Лечащий врач, 2015, 6: 66-72. /Putilina MV. Chronic cerebral ischemia. Lechashchy Vrach, 2015, 6: 66-72.
6. Vakhnina NV. Differential diagnosis of neurological disorders in patients with arterial hypertension. Сonsilium Medicum, 2016, 18 (2): 112-117.
7. Vereshchagin NV, Morgunov VA, Gulevskaya TS. Cerebral pathology in atherosclerosis and arterial hypertension. M.: Medicine, 1997; 287.
8. Damulin IV. Some diagnostic and therapeutic aspects of neurogeriatrics. Spravochnik Poliklinicheskogo Vracha, 2007, 5: 73-78
9. Schneider LS, Olin JT. Hydergine. In: Evidencebased Dementia Practice. Ed. by N Qizilbash et al. Oxford. 2002; 526-530.
10. Замерград М.В. Дифференциальный диагноз и лечение спонтанного рецидивирующего головокружения. Справочник поликлинического врача, 2016, 1: 32-35.
11. Cahn R, Borzeix MG, Legeai J. The effects of dihydroergocryptine on the neurological and enzyme disorders induced by cerebral ischemia in rats. Resuscitation, 1989; 18(1): 37-48.
12. Avedisova AS, Fayzulloev AA, Bugaeva TP. Dynamics of cognitive functions in patients with emotionally labile disorders of vascular genesis on the background of Vasobral therapy. Klinicheskaya Farmakologiya i Terapiya, 2004, 13 (2): 42-47.
13. Gudkova VV, Stakhovskaya LV, Kirilchenko TD, et al. Early rehabilitation of post-stroke patients. Consilium Medicum, 2007, 8 (8): 692-696.
14. Batysheva TT, Kostenko EV, Ganzhula PA, et al. A comprehensive program of secondary prevention of stroke: role of the combined drug Vasobral. Consilium Medicum, 2007, 2 (2): 93-96.
15. Kamchatnov PR. The results of administration of Vasobral in patients with chronic cerebrovascular disorder. Zhurnal Nevrologii i Psikhiatrii Im. S.S. Korsakova, 2011, 10: 70-72
Review
For citations:
Kostenko EV, Eneeva MA. Chronic cerebrovascular diseases: pathogenetic heterogeneity and therapeutic strategies. Meditsinskiy sovet = Medical Council. 2018;(18):50-55. (In Russ.) https://doi.org/10.21518/2079-701X-2018-18-50-55
Views:
791
Email this article 